By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Antimalarial combinations > Artemether and lumefantrine > Artemether / Lumefantrine Dosage
Antimalarial combinations
https://themeditary.com/dosage-information/artemether-lumefantrine-dosage-7522.html

Artemether / Lumefantrine Dosage

Drug Detail:Artemether and lumefantrine (Artemether and lumefantrine [ ar-tem-e-ther-and-loo-me-fan-treen ])

Drug Class: Antimalarial combinations

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Malaria

Less than 35 kg: Usual pediatric dose

At least 35 kg: 4 tablets orally as a single initial dose, followed by 4 tablets after 8 hours, and then 4 tablets twice a day (morning and evening) for the following 2 days

  • Total course: 24 tablets

Comments:
  • A 3-day treatment regimen, with a total of 6 doses

Use: For the treatment of acute uncomplicated malaria infections due to Plasmodium falciparum

Usual Pediatric Dose for Malaria

2 months or older:

  • Weight 5 to less than 15 kg: 1 tablet orally as a single initial dose, followed by 1 tablet after 8 hours, and then 1 tablet twice a day (morning and evening) for the following 2 days
  • Total course: 6 tablets
  • Weight 15 to less than 25 kg: 2 tablets orally as a single initial dose, followed by 2 tablets after 8 hours, and then 2 tablets twice a day (morning and evening) for the following 2 days
  • Total course: 12 tablets
  • Weight 25 to less than 35 kg: 3 tablets orally as a single initial dose, followed by 3 tablets after 8 hours, and then 3 tablets twice a day (morning and evening) for the following 2 days
  • Total course: 18 tablets
  • Weight At least 35 kg: 4 tablets orally as a single initial dose, followed by 4 tablets after 8 hours, and then 4 tablets twice a day (morning and evening) for the following 2 days
  • Total course: 24 tablets

Comments:
  • A 3-day treatment regimen, with a total of 6 doses

Use: For the treatment of acute uncomplicated malaria infections due to P falciparum

Renal Dose Adjustments

Renal dysfunction: No adjustment recommended.

  • Severe renal dysfunction: Caution recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended.
Severe liver dysfunction: Caution recommended.

Precautions

CONTRAINDICATIONS:

  • Known hypersensitivity to either active component or to any of the ingredients
  • Coadministration with strong CYP450 3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort)

Safety and efficacy have not been established in patients younger than 2 months or who weigh less than 5 kg.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Administer with food; although patients with acute malaria are often averse to food, encourage patients to resume normal eating as soon as food can be tolerated as this improves absorption of each component.
  • For patients unable to swallow the tablets (e.g., infants, children), crush tablet(s) and mix with a small amount of water (1 to 2 teaspoons) in a clean container for administration immediately prior to use; rinse the container with more water and swallow the contents; whenever possible, follow this crushed tablet preparation with food/drink (e.g., milk, formula, pudding, broth, porridge).
  • If vomiting occurs within 1 to 2 hours after dosing, administer a repeat dose; if the repeat dose is vomited, use an alternative antimalarial for treatment.

Storage requirements:
  • Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).

General:
  • Limitations of Use: This drug is not approved for patients with severe or complicated P falciparum malaria; this drug is not approved for prevention of malaria.
  • This drug has shown efficacy in geographical regions where chloroquine resistance has occurred.

Monitoring:
  • Cardiovascular: ECG in patients using medically-required drugs that prolong QT interval

Patient advice:
  • Read the US FDA-approved patient labeling (Patient Information).
  • Take with food.
  • Notify physician if any symptoms of QT interval prolongation (including prolonged heart palpitations, loss of consciousness) occur.
  • If using hormonal contraceptive, use an alternative nonhormonal contraceptive method or add a barrier method of contraception during therapy.
  • Stop this drug at first sign of skin rash, hives/other skin reactions, rapid heartbeat, difficult swallowing/breathing, any swelling suggesting angioedema (e.g., swelling of lips/tongue/face, tightness of throat, hoarseness), or other symptoms of allergic reaction.
Share this Article
Latest News
Medical News

Colon cancer: Exercise as important as drugs in preventing recurrence

Jun 04, 2025
Alzheimer's: Common insomnia treatment may prevent brain damage
Cholesterol: Daily cup of beans may lower levels, improve heart health
Aging and longevity: What role might coffee play?
Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk
Type 2 diabetes: Sugary drinks may significantly raise risk
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by